NDAORALCAPSULE, EXTENDED RELEASE
Approved
Jan 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
9
Data completeness
6/8 — Strong
KAPSPARGO SPRINKLE (metoprolol succinate) by Teva is 1 -selective (cardioselective) adrenergic receptor blocking agent. First approved in 2018.
Drug data last refreshed 19h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KAPSPARGO SPRINKLE is an extended-release oral capsule formulation of metoprolol succinate, a cardioselective beta-1 adrenergic receptor blocker approved in 2018. It treats hypertension, angina pectoris, and heart failure by reducing cardiac workload and oxygen demand through inhibition of catecholamine effects on the heart. The sprinkle formulation enables flexible dosing via capsule opening for patients unable to swallow intact capsules.
$0.002BPart D
Peak8.8 years to LOEProduct is at peak lifecycle with modest Part D spending (~$2M) and stable claims volume, indicating mature market with limited team expansion opportunities.
Mechanism of Action
1 -selective (cardioselective) adrenergic receptor blocking agent. This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta 2 -adrenoreceptors, chiefly located in the bronchial and vascular musculature. Metoprolol has no intrinsic…
Indications
Worked on KAPSPARGO SPRINKLE at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.